Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial


Creative Commons License

Mok T. S. , Wu Y., Kudaba I., Kowalski D. M. , Cho B. C. , TURNA Z. H. , ...More

Lancet, vol.393, no.10183, pp.1819-1830, 2019 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 393 Issue: 10183
  • Publication Date: 2019
  • Doi Number: 10.1016/s0140-6736(18)32409-7
  • Title of Journal : Lancet
  • Page Numbers: pp.1819-1830